Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols.

Reuben Ben-DavidNeeraja TilluParissa AlerasoolChristine BieberDaniel RantiSerena TolaniJustin EisenhauerRainjade ChungEtienne LavalléeNikhil WaingankarKyrollis AttallaPeter WiklundReza MehrazinChristopher B AndersonJohn P Sfakianos

Published in: World journal of urology (2024)

Gem/Doce induction with maintenance resulted in significantly better RFS than induction-only. Combining 2 g gemcitabine with docetaxel resulted in better RFS for all-grade but not for high-grade recurrences. Further prospective trials are necessary to validate our results.

Keyphrases

muscle invasive bladder cancer
locally advanced
high grade
rectal cancer
low grade
squamous cell carcinoma